Synthetic DNA minor groove-binding drugs

Pharmacology and Therapeutics

Volumn 84, Issue 1, 1999, Pages 1-111

  Reddy, B S Praveen ^a   Sondhi, S Murari ^b   Lown, J William ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b INDIAN INSTITUTE OF TECHNOLOGY ROORKEE   (India)

Author keywords

Berenil; CC 1065; Diarylamidine; Hoechst 33258; Lexitropsins; Pentamidine; Pyrrolo 1,4 benzodiazepines

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; 4',6 DIAMIDINO 2 PHENYLINDOLE; ADOZELESIN; AMIDINE; ANTHRAMYCIN; BIZELESIN; CARZELESIN; CISPLATIN; DIMINAZENE ACETURATE; DISTAMYCIN A; DOXORUBICIN; LEXITROPSIN; PENTAMIDINE; PYRROLO[2,1 C][1,4]BENZODIAZEPINE DERIVATIVE; RACHELMYCIN; RACHELMYCIN DERIVATIVE; SYNTHETIC DNA;

ANTIMICROBIAL ACTIVITY; BINDING SITE; CRYSTAL STRUCTURE; CYTOTOXICITY; DNA DRUG COMPLEX; DRUG CONJUGATION; DRUG DESIGN; DRUG DNA BINDING; DRUG DNA INTERACTION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW;

EID: 0032824383     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(99)00021-2     Document Type: Article

References (416)

1. Abu-Daya A., Brown P.M., Fox K.R. DNA sequence preferences of several AT-selective minor groove binding ligands. Nucleic Acids Res. 23:1995;3385-3392.
2. Adams E.G., Bardiner G.J., Bhuyan B.K. Effects of U-71,184 and several other CC-1065 analogues on cell survival and cell cycle of Chinese hamster ovary cells. Cancer Res. 48:1988;109-116.
3. Adnet F., Liquier J., Taillandier E., Singh M.P., Rao K.E., Lown J.W. FTIR study of specific binding interactions between DNA minor groove binding ligands and polynucleotides. J Biomol Struct Dyn. 10:1992;565-575.
4. 2 in the 2:1 solution complexes as determined by two dimensional 1H NMR. J Med Chem. 38:1995;1140-1149.
5. Anlezark G.M., Melton R.G., Sherwood R.F., Wislon W.R., Denny W.A., Palmer B.D., Knox R.J., Friedlos F., Williams A. Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochem Pharmacol. 50:1995;609-618.
6. Anne J., DeClercq E., Eyssen H., Dann O. Antifungal and antibacterial activities of diarylamidine derivatives. Antimicrob Agents Chemother. 18:1980;231-239.
7. Arima K., Kohsaka M., Tamura K.G., Imanaka H., Sakai H. Studies on tomaymycin, a new antibiotic. Isolation and properties of tomaymycin. J Antibiot. 25:1972;437-444.
8. Aristoff P.A., Johnson P.D., Sun D., Hurley L.H. Synthesis and biochemical evaluation of the CBI-PDE-I dimer, a benzannelated analog of (+)-CC-1065 that also produces delayed toxicity in mice. J Med Chem. 36:1993;1956-1963.
9. Ashley J.N., Barber H.J., Ewins A.J., Newberg G., Self A.D.H. A chemotherapeutic comparision of the trypanocidal action of some aromatic diamidines. J Chem Soc. 103-116:1942.
10. Atwell G.J., Yaghi B.M., Turner P.R., Boyd M., O'Connor C.J., Ferguson L.R., Baguley B.C., Denny W.A. Synthesis, DNA interactions and biological activity of DNA minor groove targeted polybenzamide linked nitrogen mustards. Bioorg Med Chem. 3:1995;679-691.
11. Baguley B.C. Nonintercalative DNA-binding antitumor compounds. Mol Cell Biochem. 43:1982;167-181.
12. Bailly C., Henichart J.P. Subcellular distribution of a nitroxide spin-labeled netropsin-acridine hybrid in living KB cells. Electron spin resonance study. Biochem Biophys Res Commun. 167:1990;798-806.
13. Bailly C., Henichart J.P., Colson P., Houssier C. Drug-DNA sequence dependent interactions analyzed by ELD. J Mol Recognit. 5:1992;155-171.
14. Bailly C., Colson P., Henichart J.P., Houssier C. The different binding modes of Hoechst 33258 to DNA, studied by electric linear dichroism. Nucleic Acids Res. 21:1993;3705-3709. a.
15. Bailly C., Leclere V., Pommery N., Colson P., Houssier C., Rivalle C., Bisagni E., Henichart J.P. Binding to DNA, cellular uptake and biological activity of a distamycin-ellipticine hybrid molecule. Anticancer Drug Des. 8:1993;145-164. b.
16. Bailly C., Colson P., Houssier C., Wang H., Bathini Y., Lown J.W. Mode of DNA binding of bis-benzimidazoles and related structures studied by electric linear dichroism. J Biomol Struct Dyn. 12:1994;173-181. a.
17. Bailly C., Donkor I.O., Gentle D., Thornalley M., Waring M.J. Sequence selective binding to DNA of cis and trans-butamidine analogues of the anti-Pneumocystis carinii pneumonia drug pentamidine. Mol Pharmacol. 46:1994;313-322. b.
18. Bailly C., Colson P., Houssier C., Hamy F. The binding mode of drugs to the TAR RNA of HIV-1 studied by electric linear dichroism. Nucleic Acids Res. 24:1996;1460-1464.
19. Bailly C., Perrine D., Lancelot J.C., Saturnino C., Robba M., Waring M.J. Sequence-selective binding to DNA of bis(amidinophenoxy)alkanes related to propamidine and pentamidine. Biochem J. 323:1997;23-31.
20. 1210 cell growth. Invest New Drugs. 1:1983;103-115.
21. Baraldi P.G., Leoni A., Cacciari B., Manfredini S., Simoni D., Bergomi M., Menta E., Spinellis S. Synthesis and antitumor activity of a new class of pyrazolo[4,3-c]pyrrolo[1,2-a][1,4]diazepine analogs of pyrrolo[2,1-c][1,4]benzodiazepines. J Med Chem. 37:1994;4329-4337.
22. Barcelo F., Portugal J. Berenil recognizes and changes the characteristics of adenine and thymine polynucleotide structures. Biophys Chem. 47:1993;251-260.
23. Barcellona M.L., Gratton E. Fluorescence lifetime distributions of DNA-4′,6-diamidino-2-phenylindole complex. Biochim Biophys Acta. 993:1989;174-178.
24. Barcellona M.L., Gratton E. The fluorescence properties of a DNA probe, 4′,6-diamidino-2-phenylindole (DAPI). Eur Biophys J. 17:1990;315-323.
25. Barkley M.D., Cheatham S., Thurston D.E., Hurley L.H. Pyrrolo[1,4]benzodiazepine antitumor antibiotics, evidence for two forms of tomaymycin bound to DNA. Biochemistry. 25:1986;3021-3031.
26. Bartulewicz D., Bielawski K., Krajewska D., Rozansk A. Synthetic analogues of netropsin and distamycin. II. Synthesis of a carbocyclic analogue of the pyrrolcarbooxamide antitumor antibiotics. Rocz Akad Med Bialymst. 40:1995;364-375.
27. Bates H.M., Kuenzig W., Watson W.B. Studies on the mechanism of action of anthramycin methyl ether, a new antitumor antibiotic. Cancer Res. 29:1969;2195-2205.
28. Bathini Y., Rao K.E., Shea R.G., Lown J.W. Molecular recognition between ligands and nucleic acids. novel pyridine and benzoxazole containing agents related to Hoechst-33258 that exhibit altered DNA sequence specificity deduced from footprinting analysis and spectroscopic studies Chem Res Toxicol. 3:1990;268-280.
29. Beerman T.A., McHugh M.M., Sigmund R., Lown J.W., Rao K.E., Bathini Y. Effects of analogs of the DNA minor groove binder Hoechst-33258 on topoisomerase II and I mediated activities. Biochim Biophys Acta. 1131:1992;53-61.
30. Bellorini M., Monocollin V., D'Incalci M., Mongelli N., Mantovani R. Distamycin A and tallimustin inhibit TBP binding and basal in vitro. Nucleic Acids Res. 23:1995;1657-1663.
31. Bhuyan B.K., Newell K.A., Crampton S.L., Von Hoff D. CC-1065 (NSC-298223), a most potent antitumor agent, kinetics of inhibition of growth DNA synthesis, and cell survival. Cancer Res. 42:1982;3532-3537.
32. Bhuyan B.K., Smith K.S., Adams E.G., Petzold G.L., McGovern J.P. Lethality, DNA alkylation, and cell cycle effects of adozelesin (U-73,975) on rodent and human cells. Cancer Res. 52:1992;5687-5692. a.
33. Bhuyan B.K., Smith K.S., Adams E.G., Wallace T.L., VonHoff D.D., Li L.H. Adozelesin, a potent new alkylating agent, cell-killing kinetics and cell-cycle effects. Cancer Chemother Pharmacol. 30:1992;348-354. b.
34. Bielawski K., Bartulewicz D., Krajewska D., Rozanski A. Synthetic analogues of netropsin and distamycin. III. Synthesis of pyridine analogues of the pyrrolecarboxamide antitumor antibiotics. Rocz Akad Med Bialymst. 41:1996;293-394.
35. 1H NMR spectroscopy and molecular modelling. Proc Natl Acad Sci USA. 90:1993;10018-10022.
36. Boger D.L., Garbaccio R.M. Catalysis of the CC-1065 and duocarmycin DNA alkylation reaction. DNA binding induced conformational change in the agent results in activation Bioorg Med Chem. 5:1997;263-276.
37. Boger D.L., Han N. CC-1065/duocarmycin and bleomycin A2 hybrid agents. Lack of enhancement of DNA alkylation by attachment to noncomplementary DNA binding subunits. Bioorg Med Chem. 5:1997;233-243.
38. Boger D.L., Johnson D.S. CC-1065 and duocarmycins. unraveling the keys to a new class of naturally derived DNA alkylating agents Proc Natl Acad Sci USA. 92:1995;3642-3649.
39. Boger D.L., Munk S.A., Zarrinmayeh H. CC-1065 DNA alkylation. key studies demonstrating a noncovalent binding selectivity contribution to the alkylation selectivity J Am Chem Soc. 113:1991;3980-3983. a.
40. 32P-end labelled double stranded DNA for binding studies. Development of a protocol for examination of functional features of (+)-CC-1065 and ducaromycins that contribute to their sequence selective DNA alkylation properties. Tetrahhedron. 47:1991;2661-26682. b.
41. Boger D.L., Zarrinmayeh H., Munk S.A., Kitos P.A., Suntornwat O. Demonstration of a pronounced effect of noncovalent binding selectivity on the (+) CC-1065 DNA alkylation and identification of the pharmacophore of the alkylation subunit. Proc Natl Acad Sci USA. 88:1991;1431-1435. c.
42. 2BI) alkylation subunit. Bioorg Med Chem. 1:1993;27-38.
43. Boger D.L., Johnson D.S., Yun W., Jarby C.M. Molecular basis for sequence selective DNA alkylation by (+)- and enat-(-)-CC-1065 and related agents. alkylation site models that accommodate the offset AT-rich adenine N3 alkylation selectivity Bioorg Med Chem. 2:1994;115-135.
44. Boger D.L., Yun W., Han N. 1,2,9,9a-Tetrahydrocyclopropa[c]benz[e]indole-4-one (CBI) analogues of CC-1065 and the ducarmycins. synthesis and evaluation Bioorg Med Chem. 3:1995;1429-1453.
45. Boger D.L., Zhou J., Cai H. Demonstration and definition of the noncovalent binding selectivity of agents related to CC-1065 by an affinity cleavage agent. noncovalent binding coincidental with alkylation Bioorg Med Chem. 4:1996;859-867.
46. Boitte N., Pommery N., Colson P., Houssier C., Waring M.J., Henichart J.P., Bailly C. Synthesis, DNA binding and cytotoxic properties of a bis(netropsin)-anthracenedione conjugate. Anticancer Drug Des. 12:1997;481-501.
47. Bose D.S., Jones G.B., Thurston D.E. New approaches to the pyrrolo[2,1-c][1,4]benzodiazepine. synthesis, DNA binding and cytotoxicity of DC-81 Tetrahedron. 48:1992;751-758. a.
48. Bose D.S., Thompson A.S., Ching J., Hartely J.A., Berardini M.D., Jenkins T.C., Neidle S., Hurley L.H., Thurston D.E. Rational design of a highly efficient irreversible DNA interstrand cross linking agent based on the pyrrolobenzodiazepine ring system. J Am Chem Soc. 114:1992;4939-4941. b.
49. Bose D.S., Thompson A.S., Smellie M., Berardini M.D., Hartely J.A., Jenkins T.C., Nediel S., Thurston D.E. Effect of linker length on DNA binding affinity, cross-linking efficiency and cytotoxicity of C8-linked pyrrolobenzodiazepine dimers. J Chem Soc Chem Commun. 1518-1520:1992;. c.
50. Bourdouxhe C., Colson P., Houssier C., Henichart J.P., Waring M.J., Denny W.A., Bailly C. Design of composite drug molecules. mutual effects on binding to DNA of an intercalator, amsacrine, and a minor groove binder, netropsin Anticancer Drug Des. 10:1995;131-154.
51. Bouziane M., Ketterle C., Helissey P., Herfeld P., LeBret M., Giorgi-Renault S., Auclair C. Sequence-directed single strand cleavage of DNA by a netropsin-flavin hybrid molecule. Biochemistry. 34:1995;14051-14058.
52. 2 adduct containing two drug molecules per duplex by NMR, fluorescence and molecular modelling studies. Biochemistry. 29:1990;2387-2403.
53. Braithwaite A.W., Baguley B.C. Existence of an extended series of antitumor compounds which bind to deoxyribonucleic acid by nonintercalative means. Biochemistry. 19:1980;1101-1106.
54. Broggini M., Coley H.M., Mongelli N., Pesenti E., Wyatt M.D., Hartley J.A., D'Incalci M. DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustin (FCE 24517), a benzoyl mustard derivative of distamycin. Nucleic Acids Res. 23:1995;81-87.
55. Brown D.G., Sanderson M.R., Skelly J.V., Jenkins T.C., Brown T., Garman E., Stuart D.I., Neidle S. Crystal structure of berenil-dodeca nucleotide complex. the role of water in sequence-specific ligand binding EMBO J. 9:1990;1329-1334.
56. Brown D.G., Sanderson M.R., Garman E., Neidle S. Crystal structure of a berenil d(CGCAAATTTGCG) complex. An example of drug-DNA recognition based on sequence-dependent structural features. J Mol Biol. 226:1992;481-490.
57. Brown P.M., Fox K.R. Minor groove binding ligands alter the rotational positioning of DNA fragments on nucleosome core particles. J Mol Biol. 262:1996;671-685.
58. Browne K.A., He G.X., Bruice T.C. Microgonotropens and their interactions with DNA quantitative evaluation of equilibrium constants for 1:1 and 2:1 binding of dien-microgonotropens-a, -b and -c as well as distamycin and Hoechst 33258 to d(GGCGCAAATTTGGCGG)/d(CCGCCAAATTTGCGCC). J Am Chem Soc. 115:1993;7072-7079.
59. Buel E., Schwartz M. DAPI, a simple sensitive alternative to ethidium bromide staining of DNA in agarose gels. Appl Theor Electrophor. 3:1993;253-255.
60. Bumma C., Cacchione S., Caneva R., Savino M. Specific interactions of 4′,6-diamidino-2-phenylindole with nucleosome. Biochem Pharmacol. 37:1988;1865-1866.
61. Chandra P., Mildner B., Dann O., Metz A. Influence of 4′,6-diamidino-2-phenylindole on the secondary structure and template activities of DNA and polyoxynucleotides. Mol Cell Biochem. 18:1977;81-86.
62. Chari R.V., Jackel K.A., Bourret L.A., Derr S.M., Tadayoni B.M., Mattocks K.M., Shah S.A., Liu C., Blattler W.A., Goldmacher V.S. Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. Cancer Res. 55:1995;4079-4084.
63. Chaudhary D., Miller D.M. The c-myc promoter binding protein (MBP-I) and TBP bind simultaneously in the minor groove of the c-myc P2 promoter. Biochemistry. 34:1995;3438-3445.
64. 2 adduct. Evidence for two covalent adducts with opposite orientations and stereochemistries at the covalent linkage site. J Med Chem. 31:1988;583-590.
65. Chen A.Y., Yu C., Gatto B., Liu L.F. DNA minor groove-binding ligands, a different class of mammalian DNA topoisomerase I inhibitors. Proc Natl Acad Sci USA. 90:1993;8131-8135.
66. Chen F.X., Zhang Y., Church K.M., Bodell W.J., Gold B. DNA cross linking, sister chromatid exchange and cytotoxicity of N-2-chloroethyl nitrosoureas tethered to minor groove binding peptides. Carcinogenesis. 14:1993;935-940.
67. Chen S.M., Leupin W., Rance M., Chazin W.J. Two dimensional NMR studies of d(GGTTAATGCGGT)·d(ACCGCATTAACC) complexed with the minor groove binding drug SN-6999. Biochemistry. 31:1992;4406-4413.
68. Chen Y.H., Yang Y., Lown J.W. Design of distamycin analogues to probe the physical origin of the antiparallel side by side oligopeptide binding motif in DNA minor groove recognition. Biochem Biophys Res Commun. 220:1996;213-218.
69. Chi H.I., Ishibashi Y., Shima A., Mihara I., Otsuka F. Use of DAPI cytofluorometric analysis of cellular DNA content to differentiate spitz nervus from malignant melanoma. J Invest Dermatol. 95:1990;154-157.
70. Chiang S.Y., Welch J., Rauscher F.J. 3rd, Beerman T.A. Effects of minor groove binding drugs on the interaction of TATA box binding protein and TFIIA with DNA. Biochemistry. 33:1994;7033-7040.
71. Chiang S.Y., Bruice T.C., Azizkham J.C., Gawron L., Beerman T.A. Targeting E2F1-DNA complexes with microgonotropen DNA binding agents. Proc Natl Acad Sci USA. 94:1997;2811-2816.
72. Ciomei M., Pastori W., Mariani M., Sola F., Grandi M., Mongelli N. New sulfonated distamycin A derivatives with bFGF complexing activity. Biochem Pharmacol. 47:1994;295-302.
73. Ciucci A., Feriotto G., Mischiati C., Gambari R., Animati F., Lombardi P., Natali P.G., Arcamone F., Giacomini P. Distamycin analogues with improved sequence-specific DNA binding activities. Biochem Pharmacol. 48:1994;1583-1591.
74. Clanton D.J., Buckheit R.W. Jr., Terpening S.J., Kiser R., Mongelli N., Borgia A.L., Schultz R., Narayanan V., Bader J.P., Rice W.G. Novel sulfonated and phosphonated analogues of distamycin which inhibit the replication of HIV. Antiviral Res. 27:1995;335-354.
75. Clark G.R., Gray E.J., Neidle S., Li Y.H., Leupin W. Isohelicity and phasing in drug-DNA sequence recognition. crystal structure of a tris(benziimidazole)-oligonucleotide complex Biochemistry. 35:1996;13745-13752. a.
76. 2 Nucleic Acids Res. 24:1996;4882-4889. b.
77. 2. the role of hydrogen bonding in minor groove drug-DNA recognition Nucleic Acids Res. 25:1997;1510-1515.
78. Cliffe S., Taylor M.L., Rutland M., Baguley B.C., Hill R.P., Wilson W.R. Combining bioreductive drugs (SR-4233 or SN-23862) with the vasoactive agents flavone acetic acid or 5,6-dimethyl xanthenono acetic acid. Int J Radiat Oncol Biol Phys. 29:1994;373-377.
79. Coleman R.S., Invergo B.J., Sakya S.M., Ishizaki T., Munk S.A., Zarrinmayeh H., Kitos P.A. Synthesis and evaluation of aborted and extended CC-1065 functional analogues. (+) and (-) CPI-PDEI3 preparation of key partial structures and definition of an additional functional role of CC-1065 central and right hand subunits J Am Chem Soc. 112:1990;4623-4632.
80. Colson P., Houssier C., Bailly C. Use of electric linear dichroism and competition experiments with intercalating drugs to investigate the mode of binding of Hoechst 33258, berenil and DAPI to GC sequences. J Biomol Struct Dyn. 13:1995;351-366.
81. Colson P., Bailly C., Houssier C. Electric linear dichroism as a new tool to study sequence preference in drug binding to DNA. Biophys Chem. 58:1996;125-140.
82. Comings D.E. Mechanisms of chromosome banding. VIII. Hoechst-33258-DNA interaction. Chromosoma. 52:1975;229-243.
83. Connors T.A., Mitchley B.C.V., Rosenoer V.M., Ross W.C.J. The effect of glucose pretreatment on the carcinostatic and toxic activities of some alkylating agents. Biochem Pharmacol. 13:1964;395-400.
84. Conte M.R., Jenkins T.C., Lane A.N. Interaction of minor-groove binding diamidine ligands with an asymmetric DNA duplex. NMR and molecular modelling studies. Eur J Biochem. 229:1995;433-444.
85. Corey M., Tidwell R.R., Fairley T.A. Structure and DNA binding activity of analogues of 1,5-bis(4-amidinophenoxy) pentane (pentamidine). J Med Chem. 35:1992;431-438.
86. Cote S., Momparler R.L. Evaluation of the antineoplastic activity of adozelesin alone and in combination with 5-aza-2′-deoxycytidine and cytosine arabinoside on DLD-1 human colon carcinoma cells. Anticancer Drugs. 4:1993;327-333.
87. Dabrowiak J.C., Goodisman J. Quantitative footprinting analysis of drug-DNA interactions. Kallenbach N.R. Chemistry and Physics of DNA-Ligand Interactions. 1990;143-174 Adenine Press, New York.
88. Dan O., Bergen G., Dermant E., Volz G. Trypanocide diamidine of 2-phenyl benzofurans, 2-phenylindene and 2-phenyl indole. Liebigs Ann Chem. 749:1971;68-89.
89. deCupis A., Ciomei M., Pirani P., Ferrera A., Ardizzoni A., Favoni R.E. Anti-insulin like growth factor-I activity of a novel polysulphonated distamycin A derivative in human lung cancer cell lines. Br J Pharmacol. 120:1997;537-543.
90. Denison L., Haigh A., D'Cunha G., Martin R.F. DNA ligands as radioprotectors, molecular studies with Hoechst-33342 and Hoechst-33258. Int J Radiat Biol. 61:1992;69-81. a.
91. Denison L., Haigh A., D'Cunha G., Martin R.F. DNA ligands as radioprotectors, molecular studies with Hoechst-33342 and Hoechst-33358. Int J Radiat Biol. 61:1992;561. b.
92. Denny W.A., Cain B.F. Potential antitumor agents. 31. Quantitative structure activity relationships for the antileukemic bis(guanyl hydrazones). J Med Chem. 22:1979;1234-1238.
93. Denny W.A., Atwell G.J., Baguley B.C., Cain B.F. Potential antitumor agents. 29. Quantitative structure activity relationship for the antileukemic bis quaternary ammonium heterocycles. J Med Chem. 22:1979;134-150.
94. Dervan P.B. Design of sequence specific DNA binding molecules. Science. 232:1986;464-471.
95. Dickerson R.E., Kopka M.L., Pjura P.E. The major and minor grooves of DNA as conduits for information transfer. Guschlbauer W., Saenger W. DNA Ligand Interaction, from Drugs to Proteins. 1987;45-62 Plenum Press, New York.
96. Ding L., Grehn L., DeClercq E., Andrei G., Snoeck R., Balzarini J., Fransson B., Ragnarsson U. Synthesis and antiviral activity of three pyrazole analogues of distamycin A. Acta Chem Scand. 48:1994;498-505.
97. Ding Z.M., Hurley L.H. DNA interstrand cross linking, DNA sequence specificity, and induced conformational changes produced by dimeric analogue of (+)-CC-1065. Anticancer Drug Des. 6:1991;427-452.
98. Donker I.O., Klein C.L., Liang L., Hill G.C. Pentamidine congeners. 3. Crystal structure and molecular modelling studies of trans-1,4-bis(4-amidinophenoxy)-2-butene. J Pharm Sci. 84:1995;448-455.
99. Dougherty G., Pigram W.J. Spectroscopic analysis of drug nucleic acid interactions. CRC Crit Rev Biochem. 12:1982;103-132.
100. Dubey D.D., Raman R. Effects of Hoechst-33258 on different cell cycle events. I. Inhibition of synthetic activities in bone marrow cells of the male rat Bandicota bengalensis. Exp Cell Res. 149:1983;419-432.
101. Durand M., Thuong N.T., Maurizot J.C. Interaction of Hoechst-33258 with a DNA triple helix. Biochimie. 76:1994;181-186. a.
102. Durand M., Thuong N.T., Maurizot J.C. Berenil complexation with a nucleic acid triple helix. J Biomol Struct Dyn. 11:1994;1191-1202. b.
103. Dusci L.J., Hackett L.P., Forbes A.M., Ilett K.F. High performance liquid chromatographic method for measurement of pentamidine in plasma and its application in an immunosuppressed patient with renal dysfunction. Ther Drug Monit. 9:1987;422-425.
104. Ebra E., Mascellani E., Pitteri A., D'Incalci M. Comparison of cell cycle phase perturbations induced by the DNA-minor groove alkylator tallimustin and by melphalan in the SW 626 cell line. Int J Cancer. 62:1995;170-175.
105. Ebrahimi S.E., Bibby M.C., Fox K.R., Douglas K.T. Synthesis, DNA binding, footprinting and in vitro antitumor studies of a metahydroxy analogue of Hoechst-33258. Anticancer Drug Des. 10:1995;463-479.
106. Edwards K.J., Jenkins T.C., Neidle S. Crystal structure of a pentamidine-oligonucleotide complex. implications for DNA-binding properties Biochemistry. 31:1992;7104-7109.
107. 2 studied in solution by NMR spectroscopy. Eur J Biochem. 211:1993;437-447.
108. Ena J., Amador C., Pasquau F., Carbonell C., Benito C., Gutirerrz F., Vilar A. Once a month administration of intravenous pentamidine to patients infected with human immune deficiency virus as prophylaxis for Pneumocystis carinii pneumonia. Clin Infect Dis. 18:1994;901-904.
109. Ericsson O., Rais M. Determination of pentamidine in whole blood, plasma and urine by high performance liquid chromatography. Ther Drug Monit. 12:1990;362-365.
110. Eriksson S., Kim S.K., Kubista M., Norden B. Binding of 4′,6-diamidino-2-phenylindole (DAPI) to AT regions of DNA. evidence for an allosteric conformational change Biochemistry. 32:1993;2987-2998.
111. 2 containing an interstrand cross-link derived from distamycin-pyrrole conjugate. Nucleic Acids Res. 24:1996;1566-1573.
112. Fahrmann J.W., Buoen L.C., Goyal S.M. Effect of bibenzimidazole derivative Hoechst-33258 on virus replication. Microbiologica. 11:1988;85-88.
113. Farmer J.D. Jr., Gustafson G.R., Conti A., Zimmt M.B., Suggs J.W. DNA binding properties of a new class of linked anthramycin analogues. Nucleic Acids Res. 19:1991;899-903.
114. 1H NMR. Biochemistry. 30:1991;11377-11388.
115. 1H NMR study of binding mode and kinetics J Med Chem. 27:1984;450-465.
116. Ferguson L.R., Denny W.A. Microbial mutagenic effects of the DNA minor groove binder pibenzimol (Hoechst-33258) and a series of mustard analogues. Mutat Res. 329:1995;19-27.
117. Ferguson-Smith M.A., Ferguson-Smith M.E., Ellis P.M., Dickson M. The sites and relative frequencies of secondary constriction of human somatic chromosomes. Cytogenetics. 1:1962;325-343.
118. Finlay G.J., Baguley B.C. Potentiation by phenyl bisbenzimidazoles of cytotoxicity of anticancer drugs directed against topoisomerase II. Eur J Cancer. 26:1990;586-589.
119. Forrow S.M., Lee M., Souhami R.L., Hartely J.A. The effect of AT and GC sequence specific minor groove binding agents on restriction endonuclease activity. Chem Biol Interact. 96:1995;125-142.
120. Fortsch I., Birch-Hirschfeld E., Schutz H., Zimmer C. Different effects of nonintercalative antitumor drugs on DNA triple helix stability. SN-18071 promotes triple helix formation J Biomol Struct Dyn. 14:1996;317-329.
121. Foster B.J., LoRusso P.M., Poplin E., Zalupski M., Valdivieso M., Wozniak A., Flaherty L., Kasunic D.A., Earhart R.H., Baker L.H. Phase I trial of adozelesin using the treatment schedule of daily × 5 every three weeks. Invest New Drugs. 13:1996;321-326.
122. Fox K.R., Sansom C.E., Stevens M.F. Footprinting studies on the sequence selective binding of pentamidine to DNA. FEBS Lett. 266:1990;150-154.
123. Fritzsche H., Akhebat A., Taillandier E., Rippe K., Jovin T.M. Structure and drug interactions of parallel-stranded DNA studied by infrared spectroscopy and fluorescence. Nucleic Acids Res. 21:1993;5085-5091.
124. 6G]AATTCGCG)-SN-6999 complex Biochemistry. 32:1993;9639-9648.
125. Garrity P.A., Wold B.J. Effects of different DNA polymerases in ligation mediated PCR. enhanced genomic sequencing and in vivo footprinting Proc Natl Acad Sci USA. 89:1992;1021-1025.
126. Gauze G.F., Preobrazhenskaya T.P., Ivanitskaya L.P., Sveshnikova M.A. Production of the antibiotic sibiromycin by Streptosporangium sibiricum. Antibiotica. 14:1969;963-969.
127. Geierstanger B.H., Jacobsen J.P., Mrksich M., Dervan P.B., Wemmer D.E. Structural and dynamic characterization of the heterodimeric and homodimeric complexes of distamycin and 1-methylimidazole-2-carboxamide-netropsin bound to the minor groove of DNA. Biochemistry. 33:1994;3055-3062. a.
128. Geierstanger B.H., Mrksich M., Dervan P.B., Wemmer D.E. Design of a GC specific DNA minor-groove binding peptide. Science. 266:1994;646-650. b.
129. Ghielmini M., Bosshard G., Capolongo L., Geroni M.C., Pesenti E., Torri V., D'Incalci M., Cavalli F., Sessa C. Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. Br J Cancer. 75:1997;878-883.
130. Giartosio A., Ferraro A., Lavaggi M.V., Allegra P., Turano C. The interaction of bisbenzimide with DNA. Physiol Chem Phys Med NMR. 16:1984;481-490.
131. Gillard A.C., Rault S., Boulouard M., Robba M. Thiazolo[4,3-c][1,4]benzodiazepines. synthesis of amidine derivatives J Heterocycl Chem. 32:1995;1741-1745.
132. Glaubiger D., Kohn K.W., Charney E. The reaction of anthramycin with DNA. properties of the complex Biochim Biophys Acta. 361:1974;303-311.
133. Glikson M., Dresner-Feigin R., Pollack A., Wolf D., Galun E., Kaspa R.T. Pentamidine induced cardiotoxicity. Isr J Med Sci. 26:1990;588-589.
134. Gonzalez V.M., Amo-Ochoa P., Perez J.M., Fuertes M.A., Masaguer J.R., Navarro-Ranninger C., Alonoso C. Synthesis, characterization, and DNA modification induced by a novel Pt-berenil compound with cytotoxic activity. J Inorg Biochem. 63:1996;57-68.
135. Goodsell D., Dickerson R.E. Isohelical analysis of DNA groove-binding drugs. J Med Chem. 29:1986;727-733.
136. Goodsell D.S., Kopka M.L., Dickerson R.E. Refinement of netropsin bound to DNA. bias and feedback in electron density map interpretation Biochemistry. 34:1995;4983-4993. a.
137. Goodsell D.S., Ng H.L., Kopka M.L., Lown J.W., Dickerson R.E. Structure of a dicationic monoimidazole bound to DNA. Biochemistry. 34:1995;16654-16661. b.
138. Gopalakrishna K., Kalia A., Royyuru A.K., Mrigank A.M., Rao M.V., Kothekar V. Theoretical study on binding of Hoechst-33258 with oligonucleotides. FEBS Lett. 215:1987;95-99.
139. Goulaouic H., Carteau S., Subra F., Mouscadet J.F., Auclair C., Sun J.S. Selective binding to polynucleotides of the hybrid intercalating groove binder bis(pyrrolecarboxamide)-oxazolopyridocarbazole, a molecular modelling study. Biochemistry. 33:1994;1412-1418.
140. Gravatt G.L., Baguley B.C., Wilson W.R., Denny W.A. DNA-directed alkylating agents. 6. Synthesis and antitumor activity of DNA minor groove-targeted aniline mustard analogues of pibenzimidazole (Hoechst-33258). J Med Chem. 37:1994;4338-4345.
141. Greenidge P.A., Jenkins T.C., Neidle S. DNA minor groove recognition properties of pentamidine and its analogs. a molecular modeling study Mol Pharmacol. 43:1993;982-988.
142. Gresh N., Pullman B. A theoretical study of nonintercalative binding of berenil and stilbamidine to double stranded (dA-dT)n oligomers. Mol Pharmacol. 25:1984;452-458.
143. Guan L.L., Zhao R., Lown J.W. Enhanced DNA alkylation activities of Hoechst-33258 analogues designed for bioreductive activation. Biochem Biophys Res Commun. 231:1997;94-98.
144. Gupta R., Wang H., Huang L., Lown J.W. Design, synthesis, DNA sequence preferential alkylation and biological evaluation of N-mustard derivatives of Hoechst-33258 analogues. Anticancer Drug Des. 10:1995;25-41.
145. Gupta R., Liu J., Xie G., Lown J.W. Novel DNA-directed alkylating agents consisting of naphthalimide, nitrogen mustard and lexitropsin moieties. synthesis, DNA sequence specificity and biological evaluation Anticancer Drug Des. 11:1996;581-596.
146. Hand I.L., Wiznia A., Porricola M. Administration of aerosolized pentamidine to HIV-infected infants. Ann NY Acad Sci. 693:1993;300-301.
147. Hanka L.J., Dietz A., Gerpheide S.A., Kuentzel S.L., Martin D.G. CC-1065 (NSC-298223), a new antitumor antibiotic. production, in vitro biological activity, microbiological assays and taxonomy of the producing microorganisms J Antibiot. 31:1978;1211-1217.
148. Hara M., Tamaoki T., Yoshida M., Morimoto M., Xlakano H. DC-102, a new glycosidic pyrrolo[1,4]benzodiazepine antibiotic produced by Streptomyces sp. J Antibiot. 41:1988;702-704.
149. Harbach P.R., Zimmer D.M., Mazurek J.H., Bhuyan B.K. Mutagenicity of the antitumor antibiotic CC-1065 and its analogues in mammalian (V79) cells and bacteria. Cancer Res. 48:1988;32-36.
150. Hard T., Fan P., Kearns D.R. A fluorescence study of the binding of Hoechst-33258 and DAPI to halogenated DNAs. Photochem Photobiol. 51:1990;77-86.
151. Harshman K.D., Dervan P.B. Molecular recognition of B-DNA by Hoechst-33258. Nucleic Acids Res. 13:1985;4825-4835.
152. Hartley J.A., McAdam S.R., Das S., Roldan M.C., Haskell M.K., Lee M. Molecular and cellular pharmacology of novel photoactive psoralen and coumarin conjugates of pyrrole and imidazole-containing analogues of netropsin. Anticancer Drug Des. 9:1994;181-197.
153. Hartley J.A., Preti C.S., Wyatt M.D., Lee M. Design, synthesis and biological evaluation of benzoic acid mustard derivatives of imidazole-containing and C-terminal carboxamide analogues of distamycin. Drug Des Discov. 12:1995;323-335.
154. Harworth I.S., Burt C., Gago F., Reynolds C.A., Richards W.G. A prototype bioreductive DNA groove binding ligand. Anticancer Drug Des. 6:1991;59-70.
155. Henichart J.P., Waring M.J., Riou J.F., Denny W.A., Bailly C. Copper dependent oxidative and topoisomerase II mediated DNA cleavage by a netropsin 4′-(9-acridinylamino)methansulfon-m-anisidide combilexin. Mol Pharmacol. 51:1997;448-461.
156. Hertzberg R.P., Hecht S.M., Reynolds V.L., Molinewe I.J., Hurley L.H. DNA sequence specificity of the pyrrolo[1,4]benzodiazepine antitumor antibiotics, methidium propyl-EDTA-iron(II) footprinting analysis of DNA binding sites for anthramycin related drugs. Biochemistry. 25:1986;1249-1258.
157. Hightower R.D., Sevin B.U., Perras J.P., Untch M., Angioli R., Ramos R., Avertte H. Comparision of U-73,975 and cisplatin cytotoxicity in fresh cervical and ovarian carcinoma specimens with ATP-chemosensitivity assay. Gynecol Oncol. 47:1992;186-190.
158. Hightower R.D., Sevin B.U., Perras J., Nguyen H., Angioli R., Untch M., Averette H. In vitro evaluation of the novel chemotherapeutic agents U-73,975, U-77,779, and U-80,244 in gynecologic cancer cell lines. Cancer Invest. 11:1993;276-282.
159. Hoschlowski J.E., Andrews W.W., Theriavit R.J., Jackson M., McAlpine J.P. Abbeymucin, a new anthramycin type antibiotic produced by a streptomycete. J Antibiot. 40:1987;145-148.
160. Houghton P.J., Cheshire P.J., Hallman J.D. 2nd, Houghton J.A. Therapeutic efficacy of the cyclopropyl pyrrolo indole, carzelesin, against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol.
161. 2 and its complex with berenil. Eur J Biochem. 204:1992;31-38.
162. Hurley L.H. Pyrrolo(1,4)benzodiazepine antitumor antibiotics. Comparative aspects of anthramycin, tomaymycin and sibiromycin. J Antibiot. 30:1977;349-370.
163. Hurley L.H., Needham-VanDevanter D.R. Covalent binding of antitumor antibiotics in the minor groove of DNA, mechanism of action of CC-1065 and pyrrolo(1,4)benzodiazepines. Acc Chem Res. 19:1986;230-237.
164. Hurley L.H., Petrusek R. Proposed structure of the anthramycin-DNA adduct. Nature. 282:1979;529-531.
165. Hurley L.H., Gairola C., Zmijewski M. Pyrrolo(1,4)benzodiazepine antitumor antibiotics, in vitro interaction of anthramycin, sibiromycin and tomaymycin with DNA using specifically radiolabelled molecules. Biochim Biophys Acta. 475:1977;521-535.
166. Hurley L.H., Allen C.S., Feola J.M., Lubawy W.C. In vitro and in vivo stability of anthramycin DNA conjugate and its potential application as an anthramycin prodrug. Cancer Res. 39:1979;3134-3140.
167. Hurley L.H., Rokem J.S., Petrusek R.L. Proposed structures of the pyrrolo(1,4)benzodiazepine antibiotic-deoxynucleic acid adducts. Biochem Pharmacol. 29:1980;1307-1310.
168. Hurley L.H., Reynolds V.L., Swenson D.H., Petzold G.L., Scahill T.A. Reaction of the antitumor antibiotic CC-1065 with DNA. structure of a DNA adduct with DNA sequence specificity Science. 226:1984;843-844.
169. Hurley L.H., Lee C.S., McGovren J.P., Mitchell M.A., Warpehoski M.A., Kelly R.C., Aristoff P.A. Molecular basis for sequence-specific DNA alkylation by CC-1065. Biochemistry. 27:1988;3886-3892.
170. Hurley L.H., Warpehoski M.A., Lee C.S., McGovren J.P., Scahill T.A., Kelly R.C., Mitchell M.A., Wicnienski N.A., Gebhard I., Johnson P.D., Bradford V.S. Sequence specificity of DNA alkylation by the unnatural enantiomer of CC-1065 and its synthetic analogues. J Am Chem Soc. 112:1990;4633-4649.
171. Itoh J., Watanabe H.O., Ishii S., Gomi S., Nagasawa M., Yamamoto A. Sibanomycin, a new pyrrolo(1,4)benzodiazepine antitumor antibiotic produced by Micromonospora species. J Antibiot. 41:1988;1281-1284.
172. Jansen K., Lincoln P., Norden B. Binding of DAPI analogue 2,5-bis(4-amidinophenyl)furan to DNA. Biochemistry. 32:1993;6605-6612.
173. 2. Biochim Biophys Acta. 1350:1997;189-204.
174. 2. Eur J Biochem. 213:1993;1175-1184.
175. Jeppesen C., Nielsen P.E. Photofootprinting of drug-binding sites on DNA using diazo and azido-9-amino acridine derivatives. Eur J Biochem. 182:1989;437-444.
176. Jin R., Breslauer K.J. Characterization of minor groove environment in a drug-DNA complex, bisbenzimide bound to the poly[d(AT)]·poly[d(AT)] duplex. Proc Natl Acad Sci USA. 85:1988;8939-8942.
177. Jones G.B., Davey C.L., Jenkins T.C., Kamal A., Kneale G.G., Neidle S., Webster G.D., Thurston D.E. The non-covalent interaction of pyrrolo[2,1-c][1,4]benzodiazepine-5,11-diones with DNA. Anticancer Drug Des. 5:1990;249-264.
178. Jorgenson K.F., Varshney U., VandeSande J.H. Interaction of Hoechst-33258 with repeating synthetic DNA polymers and natural DNA. J Biomol Struct Dyn. 5:1988;1005-1023.
179. Kamal A., Reddy B.S.P., Thurston D.E. Synthesis and antimicrobial activity of 5-thioabbeymycin, limitations of the iminothioether approach to carbinolamine-containing pyrrolobenzodiazepines. Bioorg Med Chem Lett. 3:1993;743-746.
180. Kaminsky R., Mamman M., Chuma F., Zweygarth E. Time-dose response of Trypanosoma brucei to diminazene aceturate (berenil) and in vitro simulation of drug concentration-time profiles in cattle plasma. Acta Trop. 54:1993;19-30.
181. Kapuscinski J. Dapi. a Dna specific fluorescent probe Biotech Histochem. 70:1995;220-233.
182. Karlovsky P., deCock A.W. Buoyant density of DNA-Hoechst 33258 (bisbenzimide) complexes in CsCl gradients. Hoechst-33258 binds to single AT base pairs Anal Biochem. 194:1991;192-197.
183. Katoizian-Safadi M., Cremet J.Y., Charlier M. Limitation of DNA-4′,6-diamidine-2-phenylindole assay in the presence of an excess of tRNA. Anal Biochem. 176:1989;416-419.
184. Kayser K., Baumgartner K., Gabius H.J. Cytometry with DAPI-stained tumor imprints. A reliable tool for improved intraoperative analysis of lung neoplasms. Anal Quant Cytol Histol. 18:1996;115-120.
185. Kennard O., Hunter W.N. Single crystal X-ray diffraction studies of oligonucleotides and oligonucleotide-drug complexes. Angew Chem Int Ed Engl. 30:1991;1254-1286.
186. Ketterle C., Gabarro-Arpa J., Quali M., Bouziane M., Auclair C., Helissey P., Giorgi-Renault S., Le-Bret M. Binding of Net-Fla, a netropsin-flavin hybrid molecule, to DNA. molecular mechanics and dynamics studies in vacuo and in water solution J Biomol Struct Dyn. 13:1996;963-977.
187. Khokholov D.N., Brusov R.V., Grokhovskii S.L., Nikolaev V.A., Pis'menskii V.F., Zhuze A.L., Gurskii G.V. A synthetic zinc chelating peptide competes for DNA binding sites with antibiotics, adsorbed in a minor groove. Mol Biol (Mosk). 29:1995;354-364.
188. 2] induced by interaction with 4′,6-diamidino-2-phenylindole. Biopolymers. 33:1993;1677-1686.
189. Kimura K., Ogawa M., Wakui A., Oguro M., Koyama Y., Saito T., Furue H., Ota K., Yamada K., Hoshino A., Nakamura T., Masaoka T., Taguchi T., Kimura I., Hattori T. Phase I study of a new antitumor antibiotic neothramycin. Gan to Kagaku Ryoho. 9:1982;924-929.
190. Kittler L., Bell A., Baguley B.C., Lober G. Inhibition of restriction endonucleases by DNA sequence-reading ligands. Biochem Mol Biol Int. 40:1996;263-272. a.
191. Kittler L., Wahnert U., Baguley B.C., Bailly C., Waring M.J., Lober G. Sequence-specific binding of antitumor bisquaternary ammonium heterocycles to DNA and inhibition of polymerase activity in vitro. Anticancer Drug Des. 11:1996;101-115. b.
192. Kittler L., Matesoi D., Bell A., Baguley B.C., Unger E., Lober G. Sequence-specific interactions of minor groove binders with the 154 base pair Hind III-RsaI restriction fragment of cDNA of the human Tau 40 protein involved in pathology of Alzheimer's disease. Biochem Mol Biol Int. 41:1997;143-152.
193. Kizu R., Draves P.H., Hurley L.H. Correlation of DNA sequence specificity of anthramycin and tomaymycin with reaction kinetics and bending of DNA. Biochemistry. 32:1993;8712-8722.
194. Konishi M., Ohkuma H., Naruse N., Kowaguchi H. Chicamycin, a new antitumor antibiotic. structure determination of chicamycin A and B J Antibiot. 37:1984;200-206.
195. Kohn K.W., Bono V.H. Jr., Kann H.E. Jr. Anthramycin, a new type of DNA-inhibiting antibiotic, reaction with DNA and effect on nucleic acid synthesis in mouse leukemia cells. Biochim Biophys Acta. 155:1968;121-129.
196. Kopka M.L., Goodsell D.S., Baikalov I., Grzeskowiak K., Cascio D., Dickerson R.E. Crystal structure of a covalent DNA-drug adduct. anthramycin bound to C-C-A-A-C-G-T-T-G-G and a molecular explanation of specificity Biochemistry. 33:1994;13593-13610.
197. Kopka M.L., Goodsell D.S., Han G.W., Chiu T.K., Lown J.W., Dickerson R.E. Defining GC-specificity in the minor groove. side by side binding of the di-imidazole lexitropsin to CATGGCCATG Structure. 5:1997;1033-1046.
198. Koz'mian L.I., Dudnik L.V., Shepelevtseva N.G. Role of the functional groups of the sibiromycin molecule in DNA binding. Antiobiotica. 22:1977;602-606.
199. Krishna K.G., Kumar T.K., Pandit M.W. Effect of cationic drugs on superhelical organization of DNA. Biopolymers. 33:1993;1415-1421.
200. Kroes A.C., Ermens A.A., Lindemans J., Schoester M., Abels J. The reduction of intracellular polyamines by sequential inhibition of the synthesis of decarboxylated S-adenosylmethionine. effects on rat leukemia Cancer Lett. 41:1988;295-305.
201. Kruger W.C., Prairie M.D. The origin of the DNA induced circular dichroism of CC-1065 and analogs. Chem Biol Interact. 79:1991;137-149.
202. Krueger W.C., Hatzenbuhler N.T., Prairie M.D., Shea M.H. DNA sequence recognition by the antitumor antibiotic CC-1065 and analogs of CC-1065. Chem Biol Interact. 79:1991;265-286.
203. 2 adduct. Biochemistry. 28:1989;9988-9994.
204. Kubista M., Akerman B., Norden B. Characterization of interaction between DNA 4′,6-diamidino-2-phenylindole by optical spectroscopy. Biochemistry. 26:1987;4545-4553.
205. Kubota Y., Murashige S., Fujisaki Y. Fluorescence studies of the interaction of DNA with Hoechst-33258. Nucleic Acids Symp Ser. 17:1986;219-222.
206. 1H NMR studies J Biomol Struct Dyn. 8:1990;331-357.
207. 1H NMR and restrained molecular mechanics studies J Biomol Struct Dyn. 9:1992;853-880.
208. Kunimoto S., Masuda T., Kanbayash N., Hamada M., Naganawa H., Miyamoto M., Takenchi T., Umezawa H. Mazethramycin, a new member of anthramycin group antibiotics. J Antibiot. 33:1980;665-667.
209. L'age M., Arasteh K. Unwanted drug side effects with pentamidine inhalation. Med Klin. 85(suppl. 2):1990;255-257.
210. 2 in solution studied by NMR. Biochemistry. 30:1991;1372-1385.
211. Langley D.R., Thurston D.E. A versatile and efficient synthesis of carbinolamine-containing pyrrolo[1,4]benzodiazepines via the cyclization of N-(2-aminobenzoyl)pyrrolidine-2-carboxaldehyde diethyl thioacetals. total synthesis of prothracarcin J Org Chem. 52:1987;91-97.
212. Langlois N., Andriamialisoa R.Z. Synthesis of sulfonamide analogs of the pyrrolo[1,4]benzodiazepine antibiotic abbeymycin. Heterocycles. 29:1989;1529-1536.
213. Larsen T.A., Goodsell D.S., Cascio D., Grzeskowiak K., Dickerson R.E. The structure of DAPI bound to DNA. J Biomol Struct Dyn. 7:1989;477-491.
214. Laughton C.A., Jenkins T.C., Fox K.R., Neidle S. Interaction of berenil with tyrTDNA sequence studied by footprinting and molecular modelling implications for the design of sequence specific DNA recognition agents. Nucleic Acids Res. 18:1990;4479-4488.
215. 2 and 2,5-bis(4-guanylphenyl)furan, an analogue of berenil. Structural origins of enhanced DNA-binding affinity. Biochemistry. 35:1996;5655-5661.
216. Lavery R., Zakrzewska K., Pullman B. Binding of non-intercalating antibiotics to B-DNA. a theoretical study taking into account nucleic acid flexibility J Biomol Struct Dyn. 3:1986;1155-1170.
217. Lee C.S., Gibson N.W. DNA damage and differential cytotoxicity produced in human carcinoma cells by CC-1065 analogues, U-73,975 and U-77,779. Cancer Res. 51:1991;6586-6591.
218. Lee C.S., Gibson N.W. Nucleotide preferences for DNA interstrand crosslinking induced by the cyclopropyl pyrrole indole analogue U-77,779. Biochemistry. 32:1993;2592-2600. a.
219. Lee C.S., Gibson N.W. DNA interstrand cross-links induced by the cyclopropyl pyrroloindole antitumor agent bizelisin are reversible upon exposure to alkali. Biochemistry. 32:1993;9108-9114. b.
220. Lee C.S., Pfeifer G.P., Gibson N.W. Mapping of DNA alkylation sites induced by adozelesin and bizelesin inhuman cells by ligation-mediated polymerase chain reaction. Biochemistry. 33:1994;6024-6030.
221. Lee M., Rhodes A.L., Wyatt M.D., Forrow S., Hartley J.A. GC base sequence recognition by oligo(imidazolecarboxamide) and C-terminus modified analogues of distamycin deduced from circular dichroism, proton nuclear magnetic resonance and methidiumpropylethylenediaminetetraacetate-iron(II) footprinting studies. Biochemistry. 32:1993;4237-4245.
222. Lee M., Preti C.S., Vinson E., Wyatt M.D., Hartley J.A. GC sequence specific recognition by an N-formamido, C-terminus modified and imidazole containing analogue of netropsin. J Med Chem. 37:1994;4073-4075. a.
223. Lee M., Roldan M.C., Haskell M.K., McAdam S.R., Hartley J.A. In vitro photoinduced cytotoxicity and DNA binding properties of psoralen and coumarin conjugates of netropsin analogues. DNA sequence-directed alkylation and cross link formation J Med Chem. 37:1994;1208-1213. b.
224. Lemgruber W., Batcho A.D., Schenker F. The structure of anthramycin. J Am Chem Soc. 87:1965;5793-5795. a.
225. Lemgruber W., Stefanovic V., Schenker F., Karr A., Berger J. Isolation and characterization of anthramycin, a new antitumor antibiotic. J Am Chem Soc. 87:1965;5791-5793. b.
226. LePecq J.B., Paoletti C. A fluorescent complex between ethidium bromide and nucleic acids. Physical-chemical characterization. J Mol Biol. 27:1967;87-106.
227. 2 and a minor groove binding drug. Biochemistry. 25:1986;5902-5910.
228. 13C-labelled minor groove-binding drug. FEBS Lett. 263:1990;313-316.
229. Li H., Swenson D.H., Schpok S., Kuentzel S.L., Dayton B.D., Kruger W.C. CC-1065 (NSC 298223), a novel antitumor agent that interacts strongly with double-stranded DNA. Cancer Res. 42:1982;999-1004.
230. Li L.H., Kelly R.C., Warpehoski M.A., McGovren J.P., Gebhard I., Dekoning T.F. Adozelesin, a selected lead among cyclopropyl pyrroleindole analogs of the DNA binding antibiotic, CC-1065. Invest New Drugs. 9:1991;137-148.
231. Libby P.R., Porter C.W. Inhibition of enzymes of polyamine back conversion by pentamidine and berenil. Biochem Pharmacol. 44:1992;830-832.
232. Lin M.S., Comings D.E., Alfi O.S. Optical studies of the interaction of 4′,6-diamino-2-phenylindole with DNA and metaphase chromosomes. Chromosoma. 60:1977;15-25.
233. Loontiens F.G., Regenfuss P., Zechel A., Dumortier L., Clegg R.M. Binding characteristics of Hoechst 33258 with calf thymus DNA, poly[d(A-T)], and d(CCGGAATTCCGG). multiple stoichiometries and determination of tight binding with a wide spectrum of site affinities Biochemistry. 29:1990;9029-9039.
234. Loontiens F.G., McLaughlin L.W., Diekmann S., Clegg R.M. Binding of Hoechst 33258 and 4′,6′-diamidino-2-phenylindole to self complementary decadeoxynucleotides with modified exocyclic base substituents. Biochemistry. 30:1991;182-189.
235. Lown J.W. DNA recognition by lexitropsins, minor groove binding agents. J Mol Recognit. 7:1994;79-88.
236. Lown J.W. DNA sequence recognition altered bis-benzimidazole minor groove binders. Graham B.J. Advances in DNA Sequence Specific Agents, Vol. 3. 1997;67-95 JAI Press, Greenwich.
237. Lown J.W., Joshua A.V. Molecular mechanism of binding of pyrrolo(1,4)benzodiazepine antitumor agents to deoxyribonucleic acid-anthramycin and tomaymycin. Biochem Pharmacol. 28:1979;2017-2026.
238. Lown J.W., Krowiciki K., Bhat U.G., Skorbogaty A., Ward B., Dabrowiak J.C. Molecular recognition between oligopeptides and nucleic acids. novel imidazole containing oligopeptides related to netropsin that exhibited altered DNA sequence specificity Biochemistry. 27:1983;3886-3892.
239. Lu C.P., Wu H.P., Chuang L.M., Lin B.J., Chuang C.Y., Tai T.Y. Pentamidine-induced hyperglycemia and ketosis in acquired immunodeficiency syndrome. Pancreas. 11:1995;315-316.
240. Luck G., Reinert K.E., Bauguley B., Zimmer C. Interaction of the nonintercalative antitumor drugs SN-6999 and SN-18071 with DNA. influence of ligand structure on the binding specificity J Biol Struct Dyn. 4:1987;1079-1094.
241. Lukhatanov E.A., Podyminogin M.A., Kutyavin I.V., Meyer R.B., Gamper H. Rapid and efficient hybridization-triggered cross linking within a DNA duplex by an oligodeoxyribonucleotide bearing a conjugated cyclopropyl pyrrole indole. Nucleic Acids Res. 24:1996;683-687.
242. Lyne L., VanDamme W. Local application of diminazene aceturate. an effective treatment for cutaneous leishmaniasis Ann Soc Belg Med Trop. 72:1992;13-19.
243. Mariani M., Paio A., Ciomei M., Pastori W., Franzetti C., Melegaro G., Grandi M., Mongelli N. In vitro activity of novel sulphonic derivatives of distamycin A. EXS. 61:1992;455-458.
244. Martin D.G., Biles C., Gerpheide S.A., Hanka L.J., Krueger W.C., McGovren J.P., Mizsak S.A., Neil G.L., Stewart J.C., Visser J. CC-1065 (NSC 298223), a potent new antitumor agent improved production and isolation, characterization and antitumor activity. J Antibiot. 34:1981;1119-1125.
245. Martin R.F., Denison L. DNA ligands as radiomodifiers. studies with minor groove binding bibenzimidazoles Int J Radiat Oncol Biol Phys. 23:1992;579-584.
246. Martin R.F., Kelly D.P., Roberts M., Nel P., Tursi J., Denison L., Rose M., Reum M., Pardee M. Comparative studies of UV-induced DNA cleavage by analogues of iodoHoechst 33258. Int J Radiat Biol. 66:1994;517-521.
247. Maruyama I.N., Suzuki H., Tanaka N. Mechanism of action of neothramycin. the effect on macromolecular synthesis J Antibiot. 31:1978;761-768.
248. Maruyama I.N., Tanaka N., Kondo S., Umezawa H. Fluorometric studies on neothramycin and its reaction with DNA. J Antibiot. 34:1981;427-435.
249. Matesol D., Kittler L., Bell A., Unger E., Lober G. Determination of microscopic binding constants at individual DNA base sequences for the minor groove binders Hoechst 33258, DAPI and pentamidine. Biochem Mol Biol Int. 38:1996;123-132.
250. Matsukuma S., Utakoji T. Asymmetric decondensation of the L cell heterochromatin by Hoechst 33258. Exp Cell Res. 113:1978;453-455.
251. Matsuzawa Y., Minagawa K., Yashikawa K., Matsumoto M., Doi M. Conformational dynamics of DNA affected by intercalation and minor groove binding. direct observation of large DNA Nucleic Acids Symp Ser. 25:1991;131-132.
252. McConnaughie A.W., Jenkins T.C. Novel acridine-triazenes as prototype combilexins. synthesis, DNA binding and biological activity J Med Chem. 38:1995;3488-3501.
253. McGovren J.P., Clarke G.L., Pratti E.A., Dekoning T.F. Preliminary toxicity studies with the DNA-binding antibiotic, CC-1065. J Antibiot. 37:1984;63-70.
254. McGowan P.F., Hurst R.E., Bass R.A., Wilcox L.J., Hemstreet G.P., Postier R.G. Equilibrium binding of Hoechst 33258 and Hoechst 33342 fluorochromes with rat colorectal cells. J Chem Cytochem. 36:1988;757-762.
255. McHugh M.M., Woynarowski J.M., Sigmund R.D., Beerman T.A. Effects of minor groove binding drugs on mammalian topoisomerase I activity. Biochem Pharmacol. 39:1989;2323-2328.
256. McHugh M.M., Sigmund R.D., Beerman T.A. Effects of minor groove binding drugs on campotothecin-induced DNA lesions in L1210 nuclei. Biochem Pharmacol. 39:1990;707-714.
257. Meyer J.C., Grundmann H. Fluorometric determination of DNA in epidermis and cultured fibroblasts using 4′,6-diamidino-2-phenyl indole (DAPI). Arch Dermatol Res. 276:1984;52-56.
258. Mikhailove M.V., Zasedatelev A.S., Krylov A.S., Gurskii G.V. Mechanism of AT base pairs recognition by molecules of dye Hoechst 33258. Mol Biol (Mosk). 15:1981;690-705.
259. Mildner B., Metz A., Chandra P. Interaction of 4′,6-diamidino-2-phenyl indole to nucleic acids and its implication to their template activity in RNA-polymerase reaction of E. coli bacteria and Friend-virus infected mouse spleen. Cancer Lett. 4:1978;89-98.
260. Misra V.K., Sharp K.A., Friedman R.A., Honig B. Salt effects on ligand-DNA binding minor groove binding antibiotics. J Mol Biol. 238:1994;245-263.
261. Mitchell M.A., Kelly R.C., Winnieski N.A., Hatzenbuhler N.T., Williams M.G. Synthesis and DNA cross-linking by a rigid CPI dimer. J Am Chem Soc. 113:1991;8994-8995.
262. Miyamoto M., Kondo S., Naganawa H., Maeda K., Ohno M., Umezawa H. Structure and synthesis of neothramycin. J Antibiot. 30:1977;340-343.
263. Mohamdi F., Spees M.M., Staten G.S., Marder P., Kipka J.K., Johnson D.A., Boger D.L., Zarrinmayeh H. Total synthesis and biological properties of novel antineoplastic (chloromethyl) furanoindolines, an asymmetric hydroboration mediated synthesis of the alkylation subunit. J Med Chem. 37:1994;232-239.
264. Monroe T.J., Mitchell M.A. In vivo mutagenesis induced by CC-1065 and adozelesin DNA alkylation in a transgenic mouse model. Cancer Res. 53:1993;5690-5696.
265. Montanari C.A., Tute M.S., Beezer A.E., Mitchell J.C. Determination of receptor-bound drug confirmations by QSAR using flexible fitting to derive a molecular similarity index. J Comput Aided Mol Des. 10:1996;67-73.
266. Moon J.H., Kim S.K., Sehlstedt U., Rodger A., Norden B. DNA structural features responsible for sequence-dependent binding geometries of Hoechst 33258. Biopolymers. 38:1996;593-606.
267. Mori S., Ohno T., Harada H., Aoyama T., Shioiri T. New methods and reagents in organic synthesis. a stereoselective synthesis of tilvalin and its analogs Tetrahedron. 47:1991;5051-5070.
268. Morikawa K., Yasumoto S., Yanagida M. Specificity in the interaction of 4′,6-diamidino-2-phenylindole with polynucleotides. Nucleic Acids Symp Ser. 10:1981;85-88.
269. Morris S.J., Thurston D.E., Nevell T. Evaluation of the electrophilicity of DNA binding pyrrolo[2,1-c][1,4]benzodiazepines by HPLC. J Antibiot. 43:1990;1286-1292.
270. Mountzouris J.A., Wang J.J., Thurston D.E., Hurley L.H. Comparison of a DSB-120 DNA interstrand cross linked adduct with the corresponding bis-tomaymycin adduct. an example of a successful template-directed approach to drug design based upon the monoalkylating compound tomaymycin J Med Chem. 37:1994;3132-3140.
271. Moy B.C., Prairie M.D., Krueger W.C., Bhuyan B.K. Interaction of CC-1065 and its analogues with mouse DNA and chromatin. Cancer Res. 49:1989;1983-1988.
272. Mrksich M., Wade W.S., Dwyer T.J., Geierstanger B.H., Wemmer D.E., Dervan P.B. Antiparallel side by side dimeric motif for sequence-specific recognition in the minor groove of DNA by the designed peptide 1-methylimidazole-2-carboxamide netropsin. Proc Natl Acad Sci USA. 89:1992;7586-7590.
273. Mukhapadhyay R., Madhubala R. Antileishmanial bis(guanylhydrazone) and its correlation with S-adenosylmethionine decarboxylase and polyamines. Int J Biochem Cell Biol. 27:1995;55-59.
274. Muller P.R., Wold B. In vivo footprinting of a muscle specific enhancer by ligation mediated PCR. Science. 246:1989;780-786.
275. Murray V., Martin R.F. Sequence specificity of 125 I-labelled Hoechst 33258 damage is six closely related DNA sequences. J Mol Biol. 203:1988;63-73. a.
276. Murray V., Martin R.F. Sequence specificity of 125 I-labelled Hoechst 33258 in intact human cells. J Mol Biol. 201:1988;437-442. b.
277. Naguyen H.N., Sevin B.U., Averette H., Perras J., Hightower R., Ramos R., Donato D., Penalver M. In vitro evaluation of novel chemotherapeutic agent, adozelesin, in gynecologic-cancer cell lines. Cancer Chemother Pharmacol. 30:1992;37-42. a.
278. Naguyen H.N., Sevin B.U., Averette H., Perras J., Ramos R., Donato D. Spectrum of cell-cycle kinetics of alkylating agent adozelesin in gynecological cancer cell lines. correlation with drug induced cytotoxicity J Cancer Res Clin Oncol. 118:1992;515-522. b.
279. Nairn R.S., Dodson M.L., Humphery R.M. Comparison of ethidium bromide and 4′,6-diamidino-2-penylindole as quantitative fluorescent stains for DNA in agarose gels. J Biochem Biophys Methods. 6:1982;95-103.
280. Neamati N., Mazumder A., Sunder S., Owen J.M., Tandon M., Lown J.W., Pommier Y. Highly potent bis-distamycins and lexitropsins inhibitors of human immunodeficiency virus type 1 integrase. Mol. Pharmacol. 54:1998;280-290.
281. Nikolaev V.A., Grokhovsky S.L., Surovaya A.N., Leinsoo T.A., Sidorova N.Y., Zasedatelev A.S., Zhuze A.L., Staahan G.A., Shafer R.H., Gursky G.V. Design of sequence specific DNA binding ligands that use a two stranded peptide motif for DNA sequence recognition. J Biomol Struct Dyn. 14:1996;31-47.
282. Norden B., Kuruchsev T. Analysing DNA complexes by circular and linear dichroism. J Mol Recognit. 7:1994;141-155.
283. Norden B., Tjernald F. High sensitivity linear dichroism as a tool for equilibrium analysis in biochemistry. Stability constant of DNA-ethidium bromide complex. Biophys Chem. 4:1976;191-198.
284. 2 complexed with propamidine J Med Chem. 38:1995;2317-2325.
285. Nunn C.M., Jenkins T.C., Neidle S. Crystal structure of d(CGCGAATTCGCG) complexed with propamidine, a short chain homologue of the drug pentamidine. Biochemistry. 32:1993;13838-13843.
286. 2. The effects of drug structural change on DNA minor-groove recognition. Eur J Biochem. 226:1994;953-961.
287. Palu G., Valisena S., Barcellona M.L., Masotti L., Meloni G.A. DAPI-pUC 8 complex. a tool to investigate biological effects of nucleic acid-drug interaction Biochem Biophys Res Commun. 145:1987;40-45.
288. 2 by Hoechst 33258. a high-field NMR study Biochemistry. 29:1990;10181-10190.
289. 2 Biochemistry. 33:1994;8442-8452.
290. Parkinson J.A., Sadat-Ebrahimi S., Wilton A., McKie J.H., Andrews J., Douglas K.T. Predictability of designing specific binding interactions for DNA minor groove ligands from NMR spectroscopy and molecular modelling. a copper(II)-activated DNA cleaver based on Hoechst 33258 Biochemistry. 34:1995;16240-16244.
291. Parolin C., Zanotti G., Palu G. A model for the sequence-dependent DNA binding of 4′,6-diamidino-2-phenylindole (DAPI). Biochem Biophys Res Commun. 308:1995;332-338.
292. Passadore M., Bianchi N., Feriotto G., Mischiati C., Giacomini P., Piva R., Gambari R. Differential effects of distamycin analogues on amplification of human gene sequences by polymerase-chain reaction. Biochem J. 308:1995;513-519.
293. Patel D.J. Nuclear magnetic resonance studies of drug-nucleic acid interactions at the synthetic DNA level in solution. Acc Chem Res. 12:1979;118-125.
294. Pearl L.H., Skelly J.V., Hudson B.D., Neidle S. The crystal structure of the DNA-binding drug berenil. molecular modelling studies of berenil-DNA complexes Nucelic Acids Res. 15:1987;3469-3478.
295. Pelucio M.T., Rothenhaus T., Smith M., Ward D.J. Fatal pancreatitis as a complication of therapy for HIV infection. J Emerg Med. 13:1995;633-637.
296. Perez J.M., Requena J.M., Craciunescu D., Doadrio J.C., Alonso C. Binding of Pt-pentamidine to nucleosomal DNA. studies of the antiproliferative activity of the drug against human cancer cells Chem Biol Interact. 89:1993;61-72.
297. Petrusek R.L., Anderson G.L., Garner T.F., Fannin Q.L., Kalpan D.J., Zimmer S.G., Hurley L.H. Pyrrolo(1,4)benzodiazepine antibiotics, proposed structures and characteristics of the in vitro deoxyribonucleic acid adducts of anthramycin, tomaymycin, sibiromycin and neothramycin A and B. Biochemistry. 20:1981;1111-1119.
298. Pezzoni G., Grandi M., Biasol G., Capolongo L., Ballinari D., Giuliani F.C., Barbieri B., Pastori A., Pesenti E., Mongelli N., Spreafico F. Profile of FCE 24517, a novel benzoyl mustard analogue of distamycin A. Br J Cancer. 64:1991;1047-1050.
299. Pfeifer G.P., Stegerwald S.D., Mueller P.R., Wold B., Riggs A.D. Genomic sequencing and methylation analysis by ligation mediated PCR. Science. 246:1989;810-813.
300. Pierce J.R., Zazimiec M., Tang M.S. Comparison of sequence preference of tomaymycin and anthramycin-DNA bonding by exonuclease III and λ exonuclease digestion and UVrABC nuclease incision analysis. Biochemistry. 32:1993;7069-7078.
301. Pilch D.S., Breslauer K.J. Ligand-induced formation of nucleic acid triple helices. Proc Natl Acad Sci USA. 91:1994;9332-9336.
302. Pilch D.S., Kirolos M.A., Breslauer K.J. Berenil binding to higher ordered nucleic acid structures. complexation with a DNA and RNA triple helix Biochemistry. 34:1995;16107-16124. a.
303. Pilch D.S., Kirolos M.A., Liu X., Plum G.E., Breslauer K.J. Berenil [1,3-bis(4′-amidinophenyl)triazene] binding to DNA duplexes and to RNA duplex. evidence for both intercalative and minor groove binding properties Biochemistry. 34:1995;9962-9976. b.
304. Pilch D.S., Xu Z., Sun Q., Lavoie E.J., Liu L.F., Geacintov N.E., Breslauev K.J. Characterizing the DNA binding modes of a topoisomerase I poising terbenzimidazole. evidence for both intercalative and minor groove binding properties Drug Des Discov. 13:1996;115-133.
305. Pimpinelli S., Prantera G., Rocchi A., Gatti M. Effects of Hoechst 33258 on human leukocytes in vitro. Cytogenet Cell Genet. 17:1976;114-121.
306. Pjura P.E., Grzeskowiak K., Dickerson R.E. Binding of Hoechst 33285 to the minor groove of B-DNA. J Mol Biol. 197:1987;257-271.
307. Plouvier B., Houssin R., Hecquet B., Colson P., Houssier C., Earing M.J., Henichart J.P., Bailly C. Antitumor combilexin, a thiazole containing analogue of netropsin linked to an acridine chromophore. Bioconjug Chem. 5:1994;475-481.
308. Plouvier B., Houssin R., Helbecque N., Colson P., Houssier C., Henichart J.P., Bailly C. Influence of methyl substituents of a thiazole-containing lexitropsin on the mode of binding to DNA. Anticancer Drug Des. 10:1995;155-166.
309. Poot M., Kausch K., Kohler J., Haaf T., Hoehn H. The minor groove binding DNA-ligand netropsin, distamycin A and berenil cause polyploidisation via impairment of the G2 phase of the cell cycle. Cell Struct Funct. 15:1990;151-157.
310. Portugal J. Berenil acts as a poison of eukaryotic topoisomerase II. FEBS Lett. 344:1994;136-138.
311. Portugal J., Waring M.J. Comparison of binding sites in DNA for berenil, netropsin and distamycin. a footprinting study Eur J Biochem. 167:1987;281-289.
312. Portugal J., Waring M.J. Assignment of DNA binding sites for 4′,6-diamidine-2-phenylindole and bisbenzimide (Hoechst 33258). a comparative footprinting study Biochim Biophys Acta. 949:1988;158-168.
313. Powers R., Gorenstein D.G. Two dimensional 1H and 31P NMR spectra restrained molecular dynamics structure of covalent CPI-CDPI2-oligodeoxyribonucleotide decamer complex. Biochemistry. 29:1990;9994-10008.
314. Punt C.J., Humblet Y., Roca E., Dirix L.Y., Wainstein R., Polli A., Corradino I. Tallimustine in advanced previously untreated colorectal cancer, a phase II study. Br J Cancer. 73:1996;803-804.
315. Puvvada M.S., Forrow S.A., Hartley J.A., Stephenson P., Gibson I., Jenkins T.C., Thurston D.E. Inhibition of bacteriophage T7 RNA polymerase in vitro transcription by DNA-binding pyrrolo[2,1-c][1,4]benzodiazepines. Biochemistry. 36:1997;2478-2484.
316. Quintana J.R., Lipanov A.A., Dickerson R.E. Low temperature crystallographic analysis of the binding of Hoechst 33258 to the double helical DNA dodecamer CGCGAATTCGCG. Biochemistry. 30:1991;10294-10306.
317. Rao K.E., Lown J.W. Molecular recognition between ligands and nucleic acids. DNA binding characteristics of analogues of Hoechst 33258 designed to exhibit altered base sequence recognition Chem Res Toxicol. 4:1991;661-669.
318. Reinert K.E., Stutter E., Zimmer C., Lown J.W. DNA interaction of the imidazole containing lexitropsin ImPy. titration viscometric study in comparison to netropsin J Biomol Struct Dyn. 12:1995;847-855.
319. Reinert K.E., Zimmer C., Arcamone F. Deformyl distamycin-DNA interaction. DNA conformational changes as revealed by titration rotational viscometry J Biomol Struct Dyn. 14:1996;245-253.
320. Remers W.A., Mabilia M., Hopfinger A.J. Conformations of complexes between pyrrolo(1,4)benzodiazepines and DNA segments. J Med Chem. 29:1986;2492-2503.
321. Reynolds V.L., Molineux I.J., Kaplan D.J., Swenson D.H., Hurley L.H. Reaction of the antitumor antibiotic CC-1065 with DNA location of the site of thermally induced strand breakage analysis of DNA sequence specificity. Biochemistry. 24:1985;6228-6237.
322. Reynolds V.L., McGovren J.P., Hurley L.H. The chemistry, mechanism of action and biological properties of CC-1065, a potent antitumor antibiotic. J Antibiot. 39:1986;319-334.
323. Rocchi A., DiCastro M., Prantera G. Effects of DAPI on human leukocytes in vitro. Cytogenet Cell Genet. 23:1979;250-254.
324. Ross C.F., Brougham M.J., Holloman W.K., Ross W.E. Properties of purified nuclear topoisomerase from L1210 cells. Biochim Biophys Acta. 741:1983;230-236.
325. Ross W.C.J. Increased sensitivity of the walker tumor towards aromatic nitrogen mustards carrying basic side chains following glucose pretreatment. Biochem Pharmacol. 8:1961;235-240.
326. Rossi R., Montecucco A., Capolongo L., Mezzina M., Chevallier-Lagente O., Sarasin A., Ciarrocchi G. The alkylating antitumor drug tallimustine does not induce DNA repair. Anticancer Res. 16:1996;3779-3783.
327. Rydzewski J.M., Leupin W., Chazin W. The width of the minor groove affects the binding of the bisquaternary heterocycle SN-6999 to duplex DNA. Nucleic Acids Res. 24:1996;1287-1293.
328. Samuelson P., Jansen K., Kubitsa M. Long-range interactions between DNA-bound ligands. J Mol Recognit. 7:1994;233-241.
329. Sansom C.E., Laughton C.A., Neidle S., Schwalbe C.H., Stevens M.F.G. Structural studies on bio-active compounds. Part XIV. Molecular modelling of the interactions between pentamidine and DNA. Anticancer Drug Des. 5:1990;243-248.
330. Sapse A.M., Sapse D., Jain D.C., Lown J.W. Quantum chemical studies employing an ab initio combination approach on the binding of the bis-benzimidazole Hoechst-33258. J Biomol Struct Dyn. 12:1995;857-868.
331. Schmitz H.U., Hubner W. A thermodynamic and spectroscopic study on the binding of berenil to poly(dAT) and to poly(dA) × poly(dT). Biophys Chem. 48:1993;61-74.
332. 2. Z Naturforsch Sect C Biosci. 50:1995;263-274.
333. 2. Biochemistry. 32:1993;12577-12585.
334. 1H NMR spectroscopy. Nucleic Acids Res. 18:1990;3753-3762.
335. Sessa C., Pagani O., Zurlo M.G., deJong J., Hofmann C., Lassus M., Marrari P., Strolin B.M., Cavalli F. Phase I study of the novel distamycin derivative tallimustine (FCE 24517). Ann Oncol. 5:1994;901-907.
336. Shamdas G.J., Alberts D.S., Modiano M., Wiggins C., Power J., Kasunic D.A., Elfring G.L., Earhart R.H. Phase I study of adozelesin (U-73,975) in patients with solid tumors. Anticancer Drug Des. 5:1994;10-14.
337. Shapiro T.A., England P.T. Selective cleavage of kinetoplast DNA mini-circles promoted by antitrypanosomal drugs. Proc Natl Acad Sci USA. 87:1990;950-954.
338. Shimizu K.I., Kawamoto I., Tomita F., Morimoto M., Fujumoto K. Prothracarcin, a novel antitumor antibiotic. J Antibiot. 35:1982;972-978.
339. Shiori T., Aoyama T., Yamagami N., Shimizu N., Mori N., Kohda K. Structure cytotoxicity relationship of tilivalline derivatives. Anticancer Drug Des. 10:1995;167-176.
340. Sidorova N.Y., Gazoni P., Rau D.C. Competition between netropsin and restriction nuclease EcoRI for DNA binding. J Biomol Struct Dyn. 13:1995;367-385. a.
341. Sidorova N.Y., Gazoni P., Rau D.C. Osmotic sensitivity of netropsin analogue binding to DNA. Biopolymers. 35:1995;377-384. b.
342. Singh M.P., Lown J.W. Lexitropsins. design and development of sequence-selective DNA minor groove binding agents as new chemotherapeutics Choudhary M.I. Progress in Medicinal Chemistry. 1996;49-171 Harwood Academic Publishers, Amsterdam.
343. Singh M.P., Joseph T., Kumar S., Bathini Y., Lown J.W. Synthesis and sequence specific DNA binding of a topoisomerase inhibitory analogue of Hoechst 33258 designed for altered base and sequence. Chem Res Toxicol. 5:1992;597-607.
344. Sinhary S., Ali Z., Burma D.P. The binding of berenil to Escherichia coli ribosome. Nucleic Acids Res. 4:1977;3829-3838.
345. Smellie M., Kelland L.R., Thurston D.E., Souhami R.L., Hartley J.A. Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor groove cross-linking agents. Br J Cancer. 70:1994;48-53.
346. Smith K.S., Folz B.A., Adams E.G., Bhuyan B.K. Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin. Cancer Chemother Pharmacol. 35:1995;471-482.
347. Smith P.J., Debenham P.G., Watson J.V. A role of DNA topoisomerases in the active dissociation of DNA minor groove ligand complexes. A flow cytometric study of inhibition effects. Mutat Res. 217:1989;163-172.
348. Sola F., Biasol G., Pesenti E., Farao M., DellaTorre P., Mongelli N., Grandi M. In vivo activity of novel sulphonic derivatives of distamycinA. EXS. 61:1992;459-462.
349. Sola F., Farao M., Ciomei M., Pastori A., Mongelli N., Grandi M. FCE 27266, a sulfonic distamycin derivative, inhibits experimental and spontaneous lung and liver meyastasis. Invasion Metastasis. 15:1995;222-231. a.
350. Sola F., Farao M., Pesenti E., Marsiglio A., Mongelli N., Grandi M. Antitumor activity of FCE 26644 a new growth factor complexing molecule. Cancer Chemother Pharmacol. 36:1995;217-222. b.
351. Sondhi S.M., Reddy B.S.P., Lown J.W. Lexitropsin conjugates. action on DNA targets Curr Med Chem. 4:1997;313-358.
352. Spielman H.P., Fagan P.A., Bregant T.M., Little R.D., Wemmer D.E. The binding modes of a rationally designed photoactivated DNA nuclease determined by NMR. Nucleic Acids Res. 23:1995;1576-1583.
353. 2 duplex Nucleic Acids Res. 22:1994;1607-1612.
354. 6G]AATTCGCG) complexed with Hoechst 33258 or Hoechst 33342 EMBO J. 11:1992;225-232.
355. 6-ethyl-guanine:cytosine base pair. Ann NY Acad Sci. 726:1994;18-43.
356. Stevenson S. Side effects of drugs, administering pentamidine. Nurs Times. 85:1989;30-32.
357. Stokke T., Steen H.B. Multiple binding modes for Hoechst 33258 to DNA. J Histochem Cytochem. 33:1985;333-338.
358. Stokke T., Steen H.B. Binding of Hoechst 33258 to chromatin in situ. Cytometry. 7:1986;227-234.
359. Storl K., Burckhardt G., Lown J.W., Zimmer C. Studies on the ability of minor groove binders to induce supercoiling in DNA. FEBS Lett. 334:1993;49-54.
360. Subra F., Mouscadet J.F., Lavignon M., Roy C., Auclair C. Inhibition of the Moloney murine leukemia virus cycle at a post reverse transcriptional step by the netropsin intercalation hybrid molecule netropsin-oxazolopyridocarbazole. Biochem Pharmacol. 45:1993;93-99.
361. Sugiyama H., Ohnari K., Chan R.L., Hosada M., Asia A., Hiromitsu S., Saito I. A novel guanine N3 alkylation by antitumor antibiotic ducarmycin A. Tetrahedron Lett. 34:1993;2179-2182.
362. Sun D., Park H.J., Hurley L.H. Alkylation of guanine and cytosine in DNA by bizelesin. Evidence for a covalent immobilization leading to a proximity driven alkylation of normally unreactive bases by a (+)-CC-1065 cross-linking compound. Chem Res Toxicol. 6:1993;889-894.
363. Surovaya A.N., Burckhardt G., Grokhovsky S.L., Birch-Hirschfeld E., Gursky G.Y., Zimmer C. Hairpin polyamides that use parallel and antiparallel side by side peptide motifs in binding to DNA. J Biomol Struct Dyn. 14:1997;595-606.
364. Swenson D.H., Petzold G.L., Williams M.G., Li L.H., Prairie M.D., Kruger W.C. Evaluation of DNA binding characteristics of some CC-1065 analogues. Chem Biol Interact. 67:1985;199-213.
365. Tagliabue G., Filippini C., Vbezio P., D'Incalci M. Combination of the new groove alkylator tallimustine and melphalan. Eur J Cancer. 33:1997;284-287.
366. Takeuchi T., Miyamoto M., Ishizuka M., Naganawa H., Kondo S., Hamada M., Umezawa H. Neothramycins A and B, new antitumor antibiotics. J Antibiot. 29:1976;93-96.
367. Tanious F.A., Veal J.M., Buczak H., Ratmeyer L.S., Wilson W.D. DAPI (4′,6-diamidino-2-phenylindole) binds differently to DNA and RNA. minor groove binding at AT sites and intercalation at AU sites Biochemistry. 31:1992;3103-3112.
368. Teng M.K., Usman N., Frederick C.A., Wang A.H. The molecular structure of the complex of Hoechst 33258 and the DNA dodecamer d(CGCGAATTCGCG). Nucleic Acids Res. 16:1988;2671-2690.
369. Thompson A.S., Fan J.Y., Sun D., Hansen M., Hurley L.H. Determination of structural role of the internal guanine-cytosine base pair in recognition of a seven base pair sequence cross-linked by bizelesin. Biochemistry. 34:1995;11005-11016.
370. Thurston, D. E., Jones, G. B., & Davis, M. E. (1990a). Synthesis and reactivity of a novel oxazolo[2,3-c][1,4]benzobiazepine ring system with DNA recognition potential: a new class of anthramycins. J Chem Soc Chem Commun 874-876.
371. Thurston D.E., Murthy V.S., Langley D.R., Jones G.B. O-debenzylation of pyrrolo[2,1-c][1,4]benzodiazepine in the presence of carbinolamine functionality, synthesis of DC-81. Synthesis. 1:1990;81-84. b.
372. Tidwell R.R., Geratz J.D., Dann O., Volz G., Zeh D., Laewe H. Diarylamidine derivatives with one or both of the aryl moieties consisting of an indole or indole like ring. Inhibitors of arginine-specific esteroproteases. J Med Chem. 21:1978;613-623.
373. Tijssen J.P., Beekes H.W., VanSteveninck J. Localization of polyphosphates in Saccharomyces fragilis as revealed by 4′,6-diamidino-2-phenylindole fluorescence. Biochim Biophys Acta. 721:1982;394-398.
374. Tozuka Z., Takasugi H., Takaya T. Studies on tomaymycin II, total synthesis of the antitumor antibitics E- and Z-tomaymycins. J Antibiot. 36:1983;276-282. a.
375. Tozuka Z., Yazawa H., Murata M., Takaya T. Studies on tomaymycin III, synthesis and antitumor activity of tomaymycin analogues. J Antibiot. 36:1983;1699-1708. b.
376. 2. J Med Chem. 39:1996;4554-4562.
377. 2 and its interaction with minor groove binding 4′,6-diamidino-2-phenylindole. J Biol Chem. 268:1993;3944-3951.
378. 1H NMR study Nucleic Acids Res. 23:1995;1333-1340.
379. 1H NMR study J Biol Chem. 271:1996;27608-27614.
380. Tsugaya M., Washida H., Hirao N., Hachisuka Y., Sakagami H., Iwase Y. The treatment of bladder cancer by neothramycin. Hinyokika Kiyo. 32:1986;1443-1448.
381. Tuite E., Sehlstedt U., Hagmer P., Norden B., Takahashi M. Effects of minor and major groove binding drugs and intercalators on the DNA association of minor groove-binding proteins RecA and deoxyribonuclease I detected by flow linear dichroism. Eur J Biochem. 243:1997;482-492.
382. Turner P.R., Denny W.A. The mutagenic properties of DNA minor groove binding ligands. Mutat Res. 355:1996;141-169.
383. Umetskaia V.N., Rozanov I.M. Mechanism of interaction of DNA with fluorescent dye Hoechst 33258. Biofizika. 35:1990;399-401.
384. Umetskaia V.N., Rozanov I.M. Nature of the fluorescence spectra of the DNA-specific dye Hoechst 33258 in solvents and in DNA complexes. Biofizika. 36:1991;167-169.
385. VanDyke M.W., Hertzberg R.P., Dervan P.B. Map of distamycin, netropsin and actinomycin binding sites on heterogeneous DNA. DNA cleavage-inhibition patterns with methidium propyl-EDTA-Fe(II) Proc Natl Acad Sci USA. 79:1982;5470-5474.
386. Vega M.C., Garcia Saez I., Aymami J., Eritja R., VanderMarel G.A., VanBoom J.H., Rich A., Coll M. Three dimensional crystal structure of the A-tract DNA dodecamer d(CGCAAATTTGCG) complexed with minor groove binding drug Hoechst-33258. Eur J Biochem. 222:1994;721-726.
387. Vinogradov A.E., Rosanov J.M. Some properties of new DNA-specific bisbenzimidazole fluorochromes without a piperazine ring. Biotech Histochem. 68:1993;265-270.
388. Volpe D.A., Tomaszewski J.E., Parchment R.E., Garg A., Flora K.P., Murphy M.J., Grieshaber C.K. Myelotoxic effects of the bifunctional alkylating agent bizelesin on human, canine and murine myeloid progenitor cells. Cancer Chemother Pharmacol. 39:1996;143-149.
389. Wade W.S., Mrksich M., Dervan P.B. Binding affinities of synthetic peptides, pyridine-2-carboxamidonetropsin and 1-methylimidazole-2-carboxamidonetropsin, that form 2:1 complexes in the minor groove of double helical DNA. Biochemistry. 32:1993;11385-11389.
390. Walker D.L., Reid J.M., Ames M.M. Preclinical pharmacology of bizelesin, a potent bifunctional analog of the DNA-binding antibiotic CC-1065. Cancer Chemother Pharmacol. 34:1994;317-322.
391. Walton A.R., Jenkins T.C., Neidle S. Studies on 1,3-diaryltriazene analogues of berenil. molecules with potential GC base pair selectivity Acta Crystallogr. 47:1991;771-775.
392. Wang J.J., Hill G.C., Hurley L.H. Template-directed design of a DNA-DNA cross-linker based upon bis-tomaymycin duplex adduct. J Med Chem. 35:1992;2995-3002.
393. Wang Y., Gupta R., Huang L., Lown J.W. CC-1065 functional analogues possessing different electron withdrawing substituents and leaving groups. synthesis, kinetics and sequence specificity of reaction with DNA and biological evaluation J Med Chem. 36:1993;4172-4182.
394. Wang Y., Gupta R., Huang L., Lown J.W. Design, synthesis, cytotoxic properties and preliminary DNA sequencing evaluation of CPI-N-methyl pyrrole hybrids. Enhancing effect of a trans double bond linker and role of the terminal amide functionality on cytotoxic potency. Anticancer Drug Des. 11:1996;15-34.
395. Wang Z., Zimmer C., Lown J.W., Knippers R. Effects of bifunctional netropsin related minor groove binding ligands on mammalian type I DNA topoisomerase. Biochem Pharmacol. 53:1997;309-316.
396. Warpehoski M.A., Gebhard I., Kelly R.C., Kruger W.C., Li L.H., McGovren J.P., Prairie M.D., Micnieski N., Wierenga W. Stereoelectronic factors influencing the biological activity and DNA interaction of synthetic antitumor agents modeled on CC-1065. J Med Chem. 31:1988;590-603.
397. Weiland K.L., Dooley J.P. In vitro and in vivo DNA binding by the CC-1065 analogue U-73975. Biochemistry. 30:1991;7559-7565.
398. Wilson E.R., Moselen J.W., Clitte S., Denny W.A., Ware D.C. Exploiting tumor hypoxia through bioreductive release of diffusible cytotoxins. the cobalt(III)-nitrogen mustard complex 24771 Int J Radiat Oncol Biol Phys. 29:1994;323-327.
399. Wilson W.D., Tanious F.A., Barton H.J., Jones R.L., Fox K., Wydra R.L., Strekowski L. DNA sequence dependent binding modes of 4′,6-diamidino-2-phenylindole (DAPI). Biochemistry. 29:1990;8452-8461.
400. Wilson W.D., Ratmeyer L., Zhao M., Strekowski L., Boykin D. The search for structure specific nucleic acid-interactive drugs. effects of compound structure on RNA versus DNA interaction strength Biochemistry. 32:1993;4098-4104.
401. Wittung P., Kim S.K., Buchardt O., Nielson P., Norden B. Interactions of DNA binding ligands with PNA-DNA hybrids. Nucleic Acids Res. 22:1994;5371-5377.
402. Wong S.S., Sturm R.A., Michel J., Zhang X.M., Danoy P.A., McGregor K., Jacobs J.J., Kaushal A., Dong Y., Dunn I.S., Parsons P.G. Transcriptional regulation of differentiation, selectivity toxicity and ATGCAAAT binding of bisbenzimadazole derivatives in human melanoma cells. Biochem Pharmacol. 47:1994;827-837.
403. 2 Nucleic Acids Res. 23:1995;3678-3684.
404. Woynarowski J.W., McHugh M., Sigmund R.D., Beerman T.A. Modulation of topoisomerase II catalytic activity by DNA minor groove binding agents distamycin, Hoechst 33258 and DAPI. Mol Pharmacol. 35:1989;177-182. a.
405. Woynarowski J.W., Sigmund R.D., Beerman T.A. DNA minor groove binding agents interfere with topoisomerase II mediated lesions induced by epipodophyllotoxin derivative VM-26 and acridine derivative m-AMSA in nuclei from L1210 cells. Biochemistry. 28:1989;3850-3855. b.
406. Wyatt M.D., Lee M., Garbiras B.J., Souhami R.L., Hartley J.A. Sequence specificity of alkylation for a series of nitrogen mustard containing analogues of distamycin of increasing binding site size. evidence for increased cytotoxicity with enhanced sequence specificity Biochemistry. 34:1995;13034-13041.
407. Wyatt M.D., Lee M., Hartley J.A. Alkylation specificity for a series of distamycin analogues that tether chlorambucil. Anticancer Drug Des. 12:1997;49-60.
408. Yamamoto K., Kawanishi S. Enhancement and alteration of bleomycin catalyzed site-specific DNA cleavage by distamycin A and some minor groove binders. Biochem Biophys Res Commun. 183:1992;292-299.
409. Yang Y., Chen Y.H., Pon R.T., Lown J.W. Studies on cooperative binding of an extended distamycin A analogue in the minor groove of DNA by NMR spectroscopy. Biochem Biophys Res Commun. 222:1996;764-769.
410. 2 and its complex with berenil by nuclear magnetic resonance spectroscopy. Biochemistry. 29:1990;6585-6592.
411. Yoshikawa K., Matsuzawa Y., Minagawa K., Doi M., Matsumoto M. Opposite effect between intercalator and minor groove binding drug on the higher order structure of DNA as is visualized by fluorescence microscopy. Biochem Biophys Res Commun. 188:1992;1274-1279.
412. Young F.E., Nightingle S.L., Cooper E.C., Trapnell C.B. Aerosolized pentamidine approved for HIV-infected individuals at high risk for Pneumocystis carinii pneumonia. Arch Intern Med. 149:1989;2412-2413.
413. Zakrzewska K., Lavery R., Pullman B. Theoretical studies of the selective binding to DNA of two non-intercalating ligands. netropsin and SN-18071 Nucleic Acids Res. 11:1983;8825-8839.
414. Zakrzewska K., Lavery R., Pullman B. The solvation contribution to the binding energy of DNA with nonintercalating antibiotics. Nucleic Acids Res. 12:1984;6559-6574.
415. Zimmer C., Luck G. Use of circular dichroism to probe structure and drug binding to DNA. Graham B.J. Advances in DNA Sequence Specific Agents, Vol. 1. 1992;51-88 JAI Press, Greenwich.
416. Zsido T.J., Beerman T.A., Meegan R.L., Woynarowski J.M., Baker R.M. Resistance of CHO cells expressing P-glycoprotein to cyclopropyl pyrrolo indole (CPI) alkylating agents. Biochem Pharmacol. 43:1992;1817-1822.